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1. Introduction  
Epilepsy is a disorder primarily characterized by the spontaneous recurrence of unprovoked 
seizures. Seizures can be triggered by multiple factors including genetic mutations, head 
injury, toxins, a fever, high or low blood sugar, a tumor, electrolyte imbalance, drug 
withdrawal; and are also a core component of developmental and degenerative disorders 
(Loscher and Brandt 2010). However, not all patients that have seizures go on to develop 
epilepsy, and the mechanisms of epileptogenesis are still poorly understood. Only a small 
number of genetic mutations identified in ion channels or proteins associated with these 
channels have been directly linked to causing epilepsy (Greenberg and Pal 2007). In fact, 
complex epidemiological studies indicate that the interplay of environmental factors with 
relatively minor genetic alterations may contribute to the difference between the 
susceptibility to suffer seizures, and the development of epilepsy (Ottman et al. 1996). 
Evidence is emerging that epileptogenesis involves changes in the expression patterns of 
several classes of functionally or genomically-grouped genes that coordinate neural 
development, homeostasis and stress responses, and neural network formation (Lukasiuk et 
al. 2006 and references therein). This has led to speculation that minor and modifiable 
changes outside the open reading frames of affected genes could alter the course of epilepsy. 
How entire groups of genes may be co-regulated with precision during different stages of 
neural development and function could be the result of epigenetic changes in histone and 
chromatin structure and DNA methylation that accompany shifts in neural “state.”   
Chromatin structure and function can be altered to silence gene expression by DNA 
methylation leading to the recruitment of methyl-DNA binding proteins and histone 
deacetylation. Histones can also be modified at their N-terminus by phosphorylation, 
acetylation, methylation, ubiquitination, ADP ribosylation, carbonylation, SUMOylation, 
glycosylation and biotinylation. Here we will focus on DNA methylation and histone 
acetylation, and discuss how these epigenetic modifications could regulate developmental 
alterations that may contribute to the process of epileptogenesis. We will summarize how 
epigenetic changes may both regulate and be regulated by activity-dependent synaptic 
plasticity, and how involvement of common mechanisms underlying glial-neuronal 
interactions could lead to epileptogenesis. Finally, we will discuss how intervening in epilepsy 
by treating with widely-used drugs that themselves can alter chromatin state (like Valproic 
Acid) may further affect ongoing epileptogenesis, and discuss which specific epigenetic 
modifications may be novel therapeutic targets for the treatment of epilepsy. 
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2. Epigenetics and development 
With limited exceptions, all cells in the human body have an identical genotype, and yet 
development produces a wide range of differentiated cell types with distinct functions that 
form highly specialized tissues and organs. This is especially true in the immensely complex 
and highly structured central nervous system (CNS). Cells differentiate from a stem cell to 
become increasingly specialized through a process of state-dependent (stage- and lineage-
specific) gene activation and gene silencing, as many genomic regions become folded into 
heterochromatin, and are excluded from transcription (silenced) (MacDonald and Roskams 
2009). Thus, progressive cell differentiation results, in part, from the epigenetic regulation of 
gene expression, which has been operationally defined as the study of heritable changes in 
gene function that are independent of changes in the underlying DNA sequence (Berger et 
al. 2009).  
2.1 Chromatin and histone modifications 
Both DNA and its associated histone proteins are subject to epigenetic modifications that 
change the overall structure of chromatin and the physical appearance of DNA within the 
nucleus (Goldberg, Allis and Bernstein 2007) (Figure 1). The fundamental unit of eukaryotic 
chromatin is the nucleosome, and it is composed of 147 base pairs of DNA wrapped around 
an octamer of four core histone proteins (H3, H4, H2A and H2B). The core histones are 
predominantly globular with flexible tails located at the N-terminus (Luger et al. 1997, 
Strahl and Allis 2000, Wade 2001). These tails vary in length and are composed of amino 
acids that allow for at least nine distinct types of modifications: phosphorylation, 
acetylation, methylation, ubiquitination, ADP ribosylation, carbonylation, SUMOylation, 
glycosylation and biotinylation (reviewed in Kouzarides 2007). Histone modifications 
correlate with gene activation or repression (Jenuwein and Allis 2001), and recently, histone 
domains containing both activating and repressive modifications have been identified 
(Azuara et al. 2006, Bernstein et al. 2005, Bernstein et al. 2006). These modifications can be 
context-dependent allowing gene transcription or silencing depending on the localization in 
the coding region versus the regulatory regions flanking the promoter (Kouzarides 2007, 
Vakoc et al. 2005). In addition to distinct histone modifications, DNA methylation can also 
silence gene transcription; and there is evidence of significant cross-talk between these 
processes to dynamically modify chromatin structure in response to external stimuli 
(Bernstein, Meissner and Lander 2007, Fuks 2005, Goldberg et al. 2007, Kouzarides 2007). 
Both DNA and histone proteins are subject to epigenetic modifications like DNA 
methylation and histone acetylation that change the overall structure of chromatin, and alter 
the extent to which DNA is wrapped around histones and therefore the availability of genes 
to be activated.  
2.1.1 DNA methylation 
DNA methylation takes place post-synthesis, and is a chief determinant of the stability of 
gene expression states (Jaenisch and Bird 2003). In vertebrates, and in humans specifically, 
DNA methylation happens almost exclusively within cytosine–phosphate–guanine (CpG) 
dinucleotides, and 70-80% of all CpG dinucleotides are methylated (Ehrlich et al. 1982); 
(reviewed in Bird 2002, Goll and Bestor 2005). DNA methylation is catalyzed by DNA 
methyltransferases, or DNMTs, which covalently bind a methyl group to position C5 of 
cytosine residues (Bird 1992). DNA methylation represses transcription directly by  
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Fig. 1. Epigenetic regulation in the nucleosome (modified from the NIH 
http://nihroadmap.nih.gov/EPIGENOMICS/images/epigeneticmechanisms.jpg) Both DNA 
and histone proteins are subject to epigenetic modifications like DNA methylation and histone 
acetylation that change the overall structure of chromatin, and alter the extent to which DNA 
is wrapped around histones and therefore the availability of genes to be activated. 
inhibiting the binding of specific transcription factors, and indirectly, by recruiting methyl-
CpG-binding (MBD) proteins and their associated repressive chromatin remodeling 
activities (Robertson 2005). DNMT1 is the predominant enzyme in mammals, and is 
responsible for maintenance methylation (post-replicative restoration of hemi-methylated 
sites to full methylation), whereas DNMT3A and DNMT3B are thought to be involved 
primarily in de novo methylation (Laird 2003). Methylation is necessary for mammalian 
development, and mice with DNMT knocked out die during development (Li, Bestor and 
Jaenisch 1992, Okano et al. 1999). This absolute requirement for DNA methylation in 
development likely reflects the diverse range of cellular functions and pathologies to which 
it contributes, including silencing of repetitive and centromeric sequences, tissue-specific 
gene expression, genomic imprinting, maintenance of X chromosome inactivation, 
carcinogenesis and aging (Bird 2002, Jaenisch and Bird 2003, Jones and Baylin 2002, Paulsen 
and Ferguson-Smith 2001).  
2.1.2 Histone deacetylation 
Histone deacetylases (HDACs) regulate gene expression by removing the acetyl groups of 
specific lysine residues from histone protein tails, thereby increasing their positive charge, 
and enhancing their interaction with the negatively charged phosphate groups in the DNA 
backbone. The functional consequence of deacetylation is to stabilize compacted forms of 
chromatin, which can restrict binding of transcription factors to promoter regions of genes. 
This is a reversible reaction, and histone acetyl transferases (HATs) can add acetyl groups to 
lysine residues, removing the positive charge and loosening the chromatin from the histone 
core. In general, increased histone acetylation (hyperacetylation) is associated with 
increased transcriptional activity, whereas decreased acetylation (deacetylation or 
hypoacetylation) is associated with repression of gene expression (Strahl and Allis 2000, 
Wade 2001). There are four main classes of HDACs which are grouped into class I, class II, 
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class III and class IV based on their sequence homology to their yeast orthologues Rpd3, 
HdaI and Sir2, respectively (de Ruijter et al. 2003, Gregoretti, Lee and Goodson 2004). The 
classical HDACs are comprised of Class I (HDACs 1, 2, 3, and 8), Class II (HDACs 4, 5, 6, 7, 
9, and 10), and Class IV (HDAC 11), and are zinc-dependent enzymes with divergent 
patterns of expression in the brain (Bjerling et al. 2002, Fischle et al. 2002, Yang and Seto 
2008). Class I HDACs have a highly conserved sequence homology and are relatively small 
proteins (377–488 amino acids) that primarily localize in the nucleus. Class II HDACs are 
larger proteins (669–1215 amino acids) that are capable of shuttling in and out of the nucleus 
in response to cellular signals like activity-dependent calcium release (de Ruijter et al. 2003, 
Yang and Seto 2008). The lone class IV member, HDAC11, shows sequence similarity to both 
class I and class II HDACs, but phylogenetic analysis reveals that it is divergent enough to 
warrant a separate class (Gao et al. 2002, Gregoretti et al. 2004). Class III HDACs or sirtuins 
are nicotinamide adenine dinucleotide (NAD+) dependent and may be important for 
linking metabolic state in cells to gene expression (Guarente and Picard 2005).  
3. Epigenetically regulated developmental changes in the brain can lead to 
epilepsy 
As many cell types throughout the brain differentiate, there is a concurrent shift in 
expression of DNMTs, HATs and HDACs that subsequently alter the compaction of 
chromatin. Developmental changes in epigenetic state thus underlie distinct shifts in gene 
expression that ultimately allow for structural and functional organization of the brain 
through control of neuro- and gliogenesis, and activity-dependent synaptic plasticity. Each 
stage of neural development carries a signature gene expression pattern, with a progressive 
restriction in the expression of developmentally regulated genes as maturation proceeds 
(Schuurmans and Guillemot 2002, Tietjen et al. 2003, Abramova et al. 2005, Lim et al. 2006). 
How repression or silencing as a result of epigenetic changes in chromatin contributes to 
these shifts in gene expression is slowly becoming better understood. Perhaps more 
importantly, improper regulation of each of these steps can lead to a variety of pathologies - 
apoptosis, alterations in neuro- and gliogenesis, aberrant neuronal migration, ectopic 
integration of neurons and glia causing structural malformations, and the formation of 
hyperexcitable circuits, all of which may contribute to seizure activity. Moreover, seizure 
activity itself can exacerbate many of these pathologies, and further perturb epigenetic 
factors, resulting in epileptogenesis and cognitive impairment.   
3.1 Methylation state modulates neuro- and gliogenesis 
In general, the known developmental effects of DNA methylation on gene expression 
involve long-term silencing of gene expression such as the establishment of parental-specific 
imprints during meiosis and X-chromosome inactivation (Jaenisch and Bird 2003), but 
recently much attention has been paid to its role in regulating gene expression during 
neuro- and gliogenesis. DNMTs are directly involved in neuronal maturation and survival 
(Fan et al. 2001, MacDonald, Gin and Roskams 2005, Feng et al. 2005). In a study by Fan and 
colleagues, conditional knock out of DNMT1 in nestin-positive cells is prenatal lethal, but 
mosaic mice with 30% of their neural cells missing DNMT1 survive into adulthood (Fan et 
al. 2001). In these animals, DNMT1-deficient neural precursor cells give rise to hypo-
methylated progeny cells, including postmitotic neurons. However, within three weeks 
postnatal, all DNMT1-negative cells are eliminated, suggesting that these neurons were not 
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stable enough to functionally mature (Fan et al. 2001). The de novo DNMTs (DNMT3a and 
DNMT3b) are sequentially expressed during neurogenesis, and are critical for regulating 
genes directly implicated in neurogenesis and neural function (Jin et al. 2008, Feng et al. 2005). 
Dnmt3b may be important for the early phase of neurogenesis, while Dnmt3a regulates 
prenatal progenitors as well as the maturation of post-mitotic neurons (Feng et al. 2005).  
DNMT1 is also a critical cell-intrinsic determinant of astrocyte differentiation. For example, the 
promoter of glial fibrillary acid protein (GFAP) is methylated in progenitor cells during the 
neurogenic stages of embryonic development, but at later stages during gliogenesis, the 
promoter becomes demethylated (Teter et al. 1996). Methylation of the STAT binding element 
within the GFAP promoter inhibits association of activated STATs with the glial promoter 
(Takizawa et al. 2001), thereby repressing transcription of GFAP and preventing cells from 
proceeding down an astroglial lineage during the neurogenic stages of brain development 
(reviewed in MacDonald and Roskams 2009). However, if DNMT1 is knocked out, precocious 
astroglial differentiation occurs, presumably through hypomethylation of the GFAP promoter 
and other genes encoding the core components of the gliogenic JAK-STAT pathway (Fan et al. 
2005). Since neurons rely on radial glial cells in order to migrate to the appropriate position 
during development, one consequence of precocious astrocyte formation could be the loss of 
radial glial “guide wires” and subsequent structural malformations caused by aberrant 
neuronal migration. These structural malformations are increasingly being discovered in 
epileptic patients as brain imaging technology advances (Scaravilli 1998).  
MBD proteins are also regulators of neurogenesis, particularly in adult neurogenic niches like 
the subventricular zone. While MBD1 knockout mice are viable and appear relatively normal, 
they do have decreased neuronal differentiation of adult stem cells and diminished 
hippocampal neurogenesis (Zhao et al. 2003). MeCP2 is perhaps the best characterized MBD 
protein, because mutations within its coding region cause Rett syndrome (Amir et al. 1999, 
Bienvenu and Chelly 2006). Analysis of MeCP2 knockout mice revealed aberrant regulation of 
factors responsible for neurotransmitter biosynthesis and for promoting the differentiation and 
maturation of various neural cell types (Urdinguio et al. 2008), suggesting that MeCP2 
regulates genes that are known to be involved in epileptogenesis. Furthermore, because 
seizures occur in many Rett patients (Glaze, Schultz and Frost 1998), there is strong evidence 
for a direct relationship between dysregulated MBD proteins and epilepsy.         
3.2 Acetylation state modulates neuro- and gliogenesis 
HDAC1 and HDAC2 are expressed at distinct stages of neuronal commitment and 
differentiation during CNS development (MacDonald and Roskams 2008), allowing them to 
modulate gene expression across neurodevelopmental stages. HDAC1 is enriched in 
progenitors clustered in neurogenic zones throughout the CNS (MacDonald and Roskams 
2008). Neural progenitors that maintain the expression of HDAC1 largely differentiate into 
glial cells, while those that lose HDAC1 expression and begin to upregulate HDAC2 
differentiate into neurons (MacDonald and Roskams 2008). In fact, HDAC1 is also highly 
expressed in the corpus callosum during oligodendrocyte differentiation, and when HDACs 
are inhibited, oligodendrocytes fail to differentiate and cause hypomyelination in the corpus 
callosum of postnatal rats (Shen, Li and Casaccia-Bonnefil 2005). Further to this, an elegant 
body of work has placed Class 1 HDACs, and HDAC1 in particular, as a critical regulator of 
the production and differentiation of oligodendrocyte precursor cells (Shen and Casaccia-
Bonnefil 2008). HDAC1 can also directly regulate stem cell proliferation, as HDAC1 null 
animals display a significant reduction in cell proliferation (Lagger et al. 2002). HDAC2, on 
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the other hand, is necessary to inhibit astrocyte differentiation, while HDAC1 is not 
(Humphrey et al. 2008). Taken together, HDAC2 may be involved in silencing glial gene 
expression, while HDAC1 likely silences neuronal genes. 
HDAC1 and HDAC2 have been proposed to work in concert through large multi-protein 
complexes like REST nuclear protein (RE-1 silencing transcription factor, also called NRSF) 
and Co-REST. Through these complexes, HDAC-mediated acetylation can enable the 
transcriptional repression of genes containing a repressor element-1 (RE1/NRSE) in their 
promoter (Huang, Myers and Dingledine 1999). Because many neuron-specific genes that 
encode ion channels, synaptic vesicle proteins and neurotransmitter receptors contain an 
RE-1 motif, it has been proposed that REST silences these genes in all other cell types and 
acts as a master regulator of neurogenesis and neuronal differentiation (Ooi and Wood 2007, 
Ballas and Mandel 2005, Hsieh and Gage 2005). Intriguingly, REST is responsible for 
regulating the expression of several genes implicated in epileptogenesis, including growth 
factors, ion channels, neurotransmitter receptors, gap junctions, and neurosecretory vesicles, 
as well as those involved in seminal neural developmental processes and adult neurogenesis 
(reviewed in Qureshi and Mehler 2009, Qureshi and Mehler 2010) 
In summary, abnormal activity of epigenetic mediators including DNMTs, MBDs, HDACs 
and repressor complexes could result in altered neuro- and gliogenesis, aberrant migration 
of newly born cells, and improper integration of these cells into circuits, thereby causing 
hyper-excitable circuits and seizures (Figure 2).  
 
 
Fig. 2. Epigenetic gene regulation can dynamically impact numerous physiological 
processes in the nervous system.  
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Epigenetic state can be altered by extrinsic factors such as environmental stimulation and 
pharmacological manipulation, and internal factors that regulate neuronal activity. Since 
epigenetic factors such as DNMTs, MBDs, HDACs and repressor complexes modulate 
processes that include neuro- and gliogenesis, neural cell migration, and activity-dependent 
synaptic plasticity; dysregulation of these epigenetic factors can lead to apoptosis, neuronal 
hyperexcitability, impaired glial function, and ultimately can contribute to seizure activity, 
epileptogenesis, and epilepsy. Conversely, the hyperexcitability associated with epilepsy 
can also impact the expression of genes that regulate epigenetic state.   
4. Epilepsy modulates epigenetic state and affects brain morphology 
Clearly a dysregulation of epigenetic factors during development causes changes in neuro- 
and gliogenesis that may increase the likelihood of developing seizures, but the reversed 
scenario can also occur. It is now clear that seizures themselves can regulate epigenetic 
factors that then affect neurogenesis, neuronal migration, synapse formation, and neural 
activity.  
It is well established that seizures cause alterations in neurogenesis in animal models and 
humans, but there is an age-dependent paradoxical effect in how seizures alter cell genesis 
in the CNS. For example, there is a postictal decrease in dentate granule cell birth in one 
week old rats subjected multiple brief seizures (Houser 1990, McCabe et al. 2001, Liu et al. 
2003). This postictal decrease is age-related because a similar seizure paradigm performed in 
adult rats causes an increase in dentate granule cell birth (Houser 1990, McCabe et al. 2001, 
Liu et al. 2003). Furthermore, these effects depend on the frequency and severity of the 
seizures. Acute seizure activity causes a proliferative surge in neural stem cells of the 
subgranular zone of the hippocampus leading to increased production of new neurons 
during the first few weeks after the seizure episode, while chronic epilepsy is associated 
with declined hippocampal neurogenesis (Houser 1990, Parent et al. 1997, Scharfman, 
Goodman and Sollas 2000, McCabe et al. 2001, Porter 2008, Kuruba, Hattiangady and Shetty 
2009). Surgically resected hippocampi from children with extra-hippocampal seizures also 
reveal a significant decrease in hippocampal neurons (Mathern et al. 1994), suggesting that 
the rate of cell death is exceeding the rate of neurogenesis and potential cell replacement.   
Other pathologies associated with epilepsy-induced dysregulation of epigenetic factors 
include altered neuronal migration and increased mossy fiber (MF) sprouting. Examination 
of surgically resected hippocampal tissue from patients with temporal lobe epilepsy (TLE) 
confirms aberrant supragranular inner molecular layer MF sprouting, and a pathology 
known as granule cell dispersion (GCD), which has been linked to decreased expression of 
the glycoprotein Reelin (Haas et al. 2002, Haas and Frotscher 2010, Mathern et al. 1994). 
Reelin is critical for mediating neuronal migration throughout the CNS, and hippocampal 
patterning during brain development (Stanfield and Cowan 1979, Forster, Zhao and 
Frotscher 2006), and its expression is regulated directly by promoter methylation (Levenson, 
Qiu and Weeber 2008, Kobow et al. 2009). Recently, hippocampal tissue samples from TLE 
patients revealed increased promoter methylation in TLE specimens compared to controls, 
and this was significantly correlated with GCD (Kobow et al. 2009), implying that chronic 
epilepsy can cause epigenetic changes that may exacerbate disease pathology. In fact, 
seizure activity can perturb the migration of newly born neurons postnatally, resulting in 
their ectopic location in the hilus (and even as far as CA3), aberrant synapse formation, and 
consequently enhanced excitability (Scharfman et al. 2000).  
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Seizures can induce histone modifications for a number of genes involved in neuronal 
plasticity and synapse formation, including the neurotrophin brain-derived neurotrophic 
factor (BDNF) and the glutamate receptor GluR2 (Tsankova, Kumar and Nestler 2004, 
Huang, Doherty and Dingledine 2002). Seizure activity induces acetylation of the BDNF 
promoter, thereby up-regulating BDNF (Tsankova et al. 2004). BDNF upregulation 
following seizure activity is thought to contribute to epileptogenesis, and BDNF infusion in 
epileptic animals can trigger seizure-like events (Scharfman, Goodman and Sollas 1999). In 
addition, transgenic mice that overexpress BDNF display heightened seizure susceptibility, 
spontaneous seizures and hyperexcitability of the hippocampus (Croll et al. 1999). 
Furthermore, BDNF has been shown to attenuate γ-aminobutyric acid (GABA)ergic inhibitory 
neurotransmission (Tanaka, Saito and Matsuki 1997), which can lead to an imbalance in 
neuronal excitatory transmission. At the same time, seizure activity leads to deacetylation of 
histones at the GluR2 promoter, and reduced expression of the receptor, resulting in enhanced 
AMPA receptor-mediated epileptogenesis (Sanchez et al. 2001). Thus, seizure activity can 
induce epigenetic changes that contribute to epileptogenesis, but why does this occur? It is 
highly likely that seizure activity harnesses much of the same molecular machinery involved 
in activity-dependent synapse formation and learning and memory.  
5. Epigenetic factors can both regulate, and be regulated by, synaptic 
plasticity 
Repeated patterns of synaptic transmission lead to diverse forms of synaptic plasticity at 
excitatory and inhibitory synapses, including long-term potentiation (LTP) and long-term 
depression (LTD), whereby the strength of synaptic transmission is increased or decreased 
respectively (reviewed in Malenka and Bear 2004). Certain forms of LTP and LTD are long 
lived and are dependent on lasting changes in gene expression (Borrelli et al. 2008). Based 
on the critical role that epigenetics plays in mediating lasting alterations in gene expression, 
DNA and histone modifiers are poised to provide a mechanism that both encodes and 
stabilizes these changes in synaptic strength. This is already the case in mice who over-
express HDAC2 in neurons, and exhibit decreased dendritic spine density, synapse number, 
synaptic plasticity and memory formation (Guan et al. 2009). These results suggest that 
deacetylation may cause transcriptional repression of the neuronal genes involved in 
forming and maintaining functional synapses. Since seizures result in synchronized 
neuronal firing, it is possible that they trigger the same types of epigenetic responses as LTP, 
and that aberrant stabilization of hyper-excitable circuits could lead to progressive 
epileptogenesis. Theoretically, specific treatment of the area of seizure-genesis with targeted 
HDAC2 inhibition could thus interrupt this cycle, and may be a promising therapeutic 
strategy.  
DNA methylation can also be dynamically regulated by synaptic activity. For example, 
neuronal activity and learning can produce DNA methylation of distinct genomic sites in 
the human brain (Siegmund et al. 2007), and this methylation signature varies by brain 
region (Ladd-Acosta et al. 2007). These observations are consistent with the recent findings 
that DNA methylation can occur rapidly and reversibly in the nervous system (Levenson et 
al. 2006) in contrast to the previous dogma that methylation state is permanent. BDNF 
exemplifies this principle, and is demethylated upon neuronal activity. It is proposed that 
neural activity via increases in cellular Ca2+ levels and activation of Ca2+/calmodulin 
kinases leads to the phosphorylation of MeCP2, and its release from the CoREST complexes 
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on the BDNF promoter (Ballas et al. 2005), resulting in increased BDNF expression 
(reviewed in Borrelli et al. 2008). Increased BDNF expression is associated with alterations in 
GABA receptor subunit composition which can lead to reduced neuronal inhibition 
(Lagrange, Botzolakis and Macdonald 2007), and increased excitatory neurotransmission by 
enhancing presynaptic glutamate release and phosphorylating NMDA receptors (Takei et al. 
1997, Lin et al. 1998). Thus, DNA methylation is regulated by neuronal activity, and in turn 
can also influence neural plasticity through the regulation of activity-dependent neuronal 
genes. Collectively, this neuronal excitability can play a modulatory role in learning and 
memory, but in the context of disease, it can feed-forward into the cycle of epileptogenesis.  
6. Environmental and nutritional factors that influence epigenetic state and 
vulnerability to epilepsy 
In mammalian development, the prenatal and postnatal periods are characterized by dynamic 
structural and functional re-organization of the brain, as its pathways become shaped by 
stimulation and experience. During this highly plastic period, environmental experiences 
influence neural structure, synaptic strength, and consequently our behavior. There is 
increasing evidence that epigenetic factors are at the interface of environment and gene 
regulation, and that changes in epigenetic state are stable enough to be heritable, but not static, 
thereby allowing future experience to modify them. A particularly good example of this is 
maternal diet, which can cause heritable changes in epigenetic state that then alter gene 
expression and behavior in offspring. Mechanistically, protein-restricted diets can inhibit 
DNMTs and cause hypomethylation of specific gene promoters in the offspring (Lillycrop et 
al. 2007). In addition, folate and vitamin B12 are essential cofactors for the methylation cycle, 
thus deficiencies in these vitamins also inhibit DNMTs and DNA methylation, which can 
cause oxidative stress and neuronal cell death (Kruman et al. 2002, Duan et al. 2002, Seshadri et 
al. 2002, Shea, Lyons-Weiler and Rogers 2002). Another B-vitamin, biotin, modulates 
chromatin regulation through histone biotinylation (Hassan and Zempleni 2006). Moreover, 
biotin deficiency can cause epilepsy as well as other clinical features including hypotonia, 
ataxia, mental retardation, and fetal malformations (Zempleni et al. 2008). These studies 
suggest that eating a diet with plenty of protein and foods rich in B vitamins may help lower 
seizure vulnerability through epigenetic regulation of gene expression. In fact, a ketogenic diet 
(high fat, adequate protein, low carbohydrate) has been used for decades to control refractory 
seizures in children (Lefevre and Aronson 2000, Stafstrom 2004), and a recent study by 
Garriga-Canut et al. provides a potential epigenetic mechanism for the antiepileptic properties 
of the ketogenic diet and of a potentially new treatment for epilepsy, 2-deoxy-D-glucose (2DG) 
(Garriga-Canut et al. 2006). Metabolic intermediates including NADH can modulate co-
activators and co-repressors, thereby linking energy availability to chromatin structure and 
transcriptional output (Guarente and Picard 2005). Since 2DG is a glycolytic inhibitor, it may 
act as a small molecule regulator of the NAD+ HDAC III sirtuins, thereby repressing 
transcription of genes that contribute to epileptogenesis. In fact, Garriga-Canut and colleagues 
(2006) show that 2DG can reduce the progression of epileptogenesis in kindled rats by raising 
the after-discharge threshold, reinforcing that diet can induce changes in epigenetic state that 
impact the development of epilepsy.  
Prenatal and postnatal stress can also influence epigenetic state and neurodevelopment, 
subsequently changing our behavior patterns. Early-life stress can cause epigenetic changes 
in the methylation status of certain promoters including the glucocorticoid receptor (GR). 
www.intechopen.com
 
Underlying Mechanisms of Epilepsy 
 
228 
Stress can increase levels of DNA methylation in the NGFI-A binding site of the GR 17 
promoter and decrease histone H3-K9 acetylation (a marker of transcriptional activation), 
the functional consequence of which is a heightened stress response (Weaver et al. 2004, 
Weaver et al. 2007). Severe early-life stress can increase excitotoxic cell death of 
hippocampal neurons (Brunson et al. 2003), whereas prenatal stress contributes to the 
susceptibility for febrile convulsions, afebrile seizures, and cerebral palsy (Greenwood et al. 
1998, Weinstock 2001). Perhaps the most striking finding is that maternal stress in the latter 
half of pregnancy lowers the seizure threshold, potentially increasing seizure susceptibility 
in the unborn offspring (Edwards et al. 2002). Thus the nervous system is particularly 
sensitive to alterations in epigenetic regulation, probably because of the fine balance needed 
to maintain heritable cellular memory while still being capable of adapting to changing 
environmental conditions.  
7. DNA methylation inhibitors and HDAC inhibitors are potential epigenetic 
targets for epilepsy treatment 
Since epigenetic factors play such an important role in regulating gene expression during 
neuro- and gliogenesis and key phases of synaptic plasticity and learning, pharmacological 
manipulation of these factors in targeted time windows in the etiology of disease holds 
enormous therapeutic potential. This is particularly important for a complex disease like 
epilepsy which involves multiple genes and downstream effectors. Recent evidence has 
emerged that modifying chromatin structure can indeed alter the disease course of epilepsy, 
and serves as a fertile ground for exploring targeted remodeling of chromatin as a potential 
therapeutic strategy in epilepsy (summarized in Table 1).  
7.1 DNA methylation inhibitors and treatment of epilepsy 
In humans, a variety of mental retardation syndromes with an epileptic phenotype 
including Rett syndrome, Fragile-X, Rubinstein–Taybi, Prader-Willi and Angelman 
syndromes, have all been linked to mutations or disruptions in methylation factors (Egger et 
al. 2004), suggesting that methylation inhibitors may be a novel therapeutic target for 
epilepsy. Current generation DNMT inhibitors are methylcytosine analogues that reduce 
DNA methylation through covalent sequestering of DNMTs as opposed to the direct 
removal of methyl groups from DNA (Juttermann, Li and Jaenisch 1994). These inhibitors 
are widely used clinically for their anti-cancer efficacy (reviewed in Das and Singal 2004), 
but have not been systematically evaluated to treat epilepsy. The DNMT inhibitors 5-
azacytidine (5azaC) and zebularine can effectively inhibit DNA methylation in neurons and 
block LTP and memory formation (Levenson et al. 2006, Miller, Campbell and Sweatt 2008, 
Miller and Sweatt 2007), suggesting that they are good candidate drugs to evaluate in 
epilepsy paradigms. When both agents were applied in a Rett syndrome mouse model, 
treatment facilitated a significant decrease in frequency of miniature excitatory post-
synaptic currents (mEPSCs) and rate of spontaneous synaptic vesicle fusion (Nelson et al. 
2008). Since decreasing mEPSCs can reduce neuronal excitability, methylation inhibitors 
may possess anti-seizure properties, and should thus be tested in more classic epilepsy 
models. In addition to methylcytosine analogs, DNA methylation can be reversed 
pharmacologically by increasing histone acetylation through the use of HDAC inhibitors 
(Cervoni and Szyf 2001, Milutinovic et al. 2007), underscoring that multiple epigenetic 
factors work in a concerted manner to regulate gene expression and careful consideration of  
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Drug name Epigenetic target (Deutsch et al. 
2008) 
Outcome Reference 
Sodium 
Butyrate 
Inhibits class 1 
and II HDACs 
except HDAC6 
and HDAC10 
IECS to produce 
tonic hindlimb 
extension 
Increased H3 and H4 
acetylation in 
hippocampus and cortex 
and improved anti-
seizure efficacy of MK-801
(Deutsch et al. 
2008) 
VPA Inhibits class I 
HDACs and to a 
lesser extent class 
II HDACs 
IBO injection 
(excitotoxin) to kill 
GABAergic and 
cholinergic neurons 
 
 
 
 
Kainic Acid 
induced SE 
 
 
 
 
 
 
 
PTZ induced 
seizures 
Increased H3 acetylation 
in cortex and NBM and 
significant protection of 
both cholinergic and 
GABAergic neurons 
present in the injected 
area  
 
No significant effect on 
seizure strength or 
frequency but inhibited 
seizure-induced 
neurogenesis in 
hippocampus and 
prevented memory 
impairment 
 
Increased thresholds to all 
seizure types 
 
(Eleuteri et al. 
2009) 
 
 
 
 
 
 
(Jessberger et 
al. 2007) 
 
 
 
 
 
 
 
(Hoffmann, 
Czapp and 
Loscher 2008) 
TSA Inhibits class I and 
II HDACs 
Kainic Acid 
induced SE 
 
 
PTZ induced 
seizures 
 
Pilocarpine 
induced seizures 
 
Kainic Acid 
induced seizures 
Prevented the down-
regulation of GluR2 in 
hippocampus 
 
No dose-dependent 
anticonvulsant effects 
 
Prevented the down-
regulation of GluR2 in 
hippocampus 
 
Histone hyperacetylation 
of IEGs c-jun and c-fos 
(Jessberger et 
al. 2007) 
 
 
(Hoffmann et 
al. 2008) 
 
(Huang et al. 
2002) 
 
 
(Sng, Taniura 
and Yoneda 
2005) 
Zebularine Inhibits DNMTs Rett Syndrome 
(MeCP2 KO mice) 
Deficits in spontaneous 
synaptic transmission  
(Nelson, 
Kavalali and 
Monteggia 
2008) 
 
Abbreviations: HDAC=histone deacetylase. SE=status epilepticus. IECS=incremental electroconvulsive 
shock. VPA=valproic acid. IBO=ibotenic acid. NBM=nucleus basalis magnocellularis. TSA=trichostatin 
A. GluR2=glutamate receptor 2. PTZ=pentylenetetrazole. IEG=immediate early genes. DNMT=DNA 
methyltransferase. KO=knock out 
Table 1. Epigenetic therapy in epilepsy models  
www.intechopen.com
 
Underlying Mechanisms of Epilepsy 
 
230 
undesired secondary effects of such compounds must be taken when designing a 
therapeutic approach.  
7.2 HDAC inhibitors and treatment of epilepsy 
HDAC inhibitors (HDACi) are classified into six groups based on their chemical structures: 
(1) hydroxamic acids, including TSA and SAHA; (2) small-molecular-weight carboxylates, 
including sodium butyrate, valproic acid, and sodium phenylbutyrate; (3) benzamides, 
including MS-275 and CI-994; (4) epoxyketones, including AOE and trapoxin B; (5) cyclic 
peptides, including depsipeptide and apicidin; and (6) hybrid molecules, such as CHAP31 
and CHAP50 (Drummond et al. 2005 and references there in). Most HDACi are broad-
spectrum within the classical HDAC family, and isoform-specific inhibitors have been difficult 
to design due to the high sequence homology within the catalytically-active sites of HDACs 
(Bieliauskas and Pflum 2008). Therefore, the majority of published studies have employed 
HDAC inhibitors that have multiple secondary targets within and beyond the CNS, but 
collectively, a compelling argument can be made to explore their efficacy in most epilepsy 
paradigms. Hydroxamic acids encompass the broadest set of HDACi, and primarily inhibit 
class I/II HDACs when used in the nanomolar range (Bieliauskas and Pflum 2008), however 
side effects in patients have been reported, particularly with TSA (Villar-Garea and Esteller 
2004). In contrast, the carboxylates are very well tolerated in animals and humans, and have 
been used in dose escalating studies in the clinic (Atmaca et al. 2007). HDAC inhibitors have 
been extensively studied in models of neurodegenerative disease (Hahnen et al. 2008), and 
some agents–such as valproic acid (VPA), sodium butyrate and LBH589–are now being tested 
in clinical trials in patients with spinal muscular atrophy (SMA), Huntington’s disease (HD), 
Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS). 
The most widely used HDAC inhibitor, Valproate (VPA), has been used as an anti-epileptic 
therapeutic agent for over 40 years, and its effects in the nervous system have recently been 
reviewed in detail elsewhere (MacDonald and Roskams 2009, Loscher 1999). However, VPA 
has primarily been used for its multitude of effects on CNS excitation pathways that have 
not taken into account its HDAC inhibition activity. Briefly, VPA can (1) increase the level of 
the inhibitory neurotransmitter γ-aminobutyric acid (GABA), (2) reduce sodium 
conductance through voltage-gated sodium channels, (3) suppress N-methyl-D-aspartate 
(NMDA) receptor-mediated excitation, (4) have teratogenic activity in both humans and 
mouse models. 
While VPA is well tolerated and can attenuate seizure activity, evidence suggests that it is 
not truly antiepileptic. In other words, VPA can acutely and chronically reduce the risk of 
recurrent seizures, but treatment does not alter the development of epilepsy (Shinnar and 
Berg 1996, Haut and Shinnar 2008). One possible explanation for this dichotomy is that even 
though VPA augments presynaptic GABA release (reviewed in Loscher 1999), thereby 
conferring antiseizure properties, VPA also increases BDNF expression (Fukumoto et al. 
2001) and can reduce GABAA receptor γ2 subunit, GAD65, GAD67, and KCC2 expression 
(Fukuchi et al., 2009), thus impairing GABAergic function over time and potentially shifting 
the balance of neurotransmission to a more hyperexcitable state. Furthermore, GABAergic 
signaling regulates neurogenesis and neuronal differentiation of immature neurons (Ben-Ari 
2002), so VPA-mediated alterations in GABAergic neurotransmission could impair 
neurogenesis and subsequently cause cognitive impairment, particularly in children and 
adolescents where brain development is still very actively occurring. In fact, mice lacking 
MeCP2 from GABA-releasing neurons consequently have impaired GABA function, and 
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display many of the characteristic symptoms of Rett syndrome and autism (Chao et al.). 
Thus, if inhibitory neurogenesis is indeed perturbed as a secondary action of this 
compound, treating patients with VPA to control seizures could inadvertently hasten the 
progression of epilepsy. However, in a recent study, treatment with VPA following kainic 
acid-induced seizures did inhibit hippocampal neurogenesis, but surprisingly improved 
cognitive impairment compared with controls who received kainic acid alone (Jessberger et 
al. 2007). This contradiction supports the hypothesis that seizure-induced neurogenesis can 
be detrimental, but the consequences of chronically inhibiting neurogenesis are likely to be 
harmful.  
A final potential use for HDAC inhibitors in treating epilepsy is in enhancing the survival of 
neurons in existing circuits that might otherwise succumb to excitotoxic cell death due to 
hyper-excitation and the resulting ionic imbalances. A growing body of evidence places 
HDAC inhibition capable of mediating survival signaling, cytoskeletal stabilization in 
neurons, and CREB-mediated signaling following ischemia and oxidative stress (reviewed 
in Sleiman et al. 2009). With the development and testing of new generations of specific 
HDAC inhibitors that are not only CNS-permeable, but usable in short-term pulses in 
animal models of appropriate neurological diseases, it is possible that HDACi-mediated 
neuroprotection and stabilization of existing brain circuitry is a potential mechanism for 
preventing the spread or progression of epilepsy, and limiting the accompanying cognitive 
deficits that result from poorly controlled seizures in epileptic patients. 
8. Conclusions 
After sequencing the human genome – and the genomes of numerous other species, it is 
apparent that organisms with a higher order of complexity within their CNS have acquired 
a more complex non-coding genome. The majority of this sequence is comprised of 
regulatory elements that contextually modulate protein expression and function. Although a 
large part of development is due to the complex transcriptional regulation required of 
multiple members of the same gene family, it is likely that analysis of the structural 
organization, the regulation of the non-coding genome, and the role of epigenetics in 
modulating these phenomena will reveal a more in-depth understanding of our own human 
phenotype. Within these unique DNA modifications are clues to the origin, susceptibility, 
and progression of neurological disease, including epilepsy.  
Epigenetic processes are certainly involved in the development and progression of epilepsy, 
and epilepsy, in turn, can change the epigenetic landscape of the CNS (summarized in  
Fig 2). Regardless of whether seizures begin early or later in life; the processes outlined 
above (synaptic plasticity, neuro-gliogenesis, and neuroprotection) are ongoing 
developmental processes that are all mediated by epigenetic changes in chromatin structure. 
Those same changes in chromatin--based on environment, stimulation, and developmental 
programs--drive the individual biology within distinct CNS cells. Thus epigenetics provides 
a mechanism whereby CNS cells can react to internal and external stimuli, and record the 
experience in both a modifiable and heritable manner. The emergence of genomic 
diagnostics, coupled with high resolution imaging to pinpoint functionally “normal” versus 
“aberrant” cellular responses to these stimuli, will allow us to identify the aberrant circuitry 
that leads to the progression of epilepsy and its underlying pathology.  
Concurrent with this, advances in combinatorial chemistry and high throughput screening 
approaches will allow for the ongoing and rapid development of subtype-specific HDAC 
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inhibitors (and drugs to modify other histone marks such as methylation and 
phosphorylation). Because the pharmacological manipulation of epigenetic factors is a 
growing target for many diseases (notably cancer), the future holds great promise in being 
able to evaluate the therapeutic efficacy of these agents in neurological diseases, and in 
particular, for the beneficial effects they may afford to patients with epilepsy. 
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